0

Back to Next-Generation Sequencing for Pediatric Tumors
Next-Generation Sequencing for Pediatric Tumors

Next-Generation Sequencing for Pediatric Tumors

Release Date: Jun 2018

CC: PC, MK, PBL, SBP

 

Matthew Hiemenz, MD, MS, FCAP

Assistant Director of Clinical Genomics, Children’s Hospital Los Angeles, Los Angeles, CA; Assistant Professor of Clinical Pathology, Keck School of Medicine of USC, Los Angeles, CA

 

 

 

Description:

 

Next generation sequencing (NGS) is a revolutionary technology that allows the testing of many types of molecular alterations (e.g., DNA point mutations, insertions/deletions, copy number variants, and fusions) simultaneously. In the clinical testing of oncology samples, NGS has primarily been applied to adult cancers, as pediatric tumors present several unique challenges. However, NGS is currently entering the realm of clinical laboratory testing of pediatric tumor samples.

This webcast will describe the utility and limitations of NGS for molecular testing of pediatric tumor samples. Examples will be drawn from a pan-cancer panel that was custom-designed and validated for use with pediatric cancer samples. Specific clinical cases will be provided of NGS as a stand-alone test as well as a complement to existing molecular testing methods such as Sanger sequencing and chromosomal microarrays. Finally, the frontiers and challenges of applying NGS approaches to all pediatric tumor cases will be explored.  

This webcast will cover core molecular oncology concepts, including NGS, in clinical laboratory testing of pediatric tumor samples. Attendees working in molecular oncology, sequencing, or pediatric laboratory testing are encouraged to participate. Knowledge of the basic fundamentals of DNA sequencing is assumed.

 

 

After attending this session, participants will be able to:

 

  • Describe the standard of care for testing for the major categories of pediatric tumors--leukemias/lymphomas, brain tumors, and sarcomas.
  • Recognize the utility of next-generation sequencing in pediatric tumors.
  • Identify the limitations of next-generation sequencing in molecular oncology as it relates to pediatric neoplasia.

 

Who should attend?  Practicing Pathologists, Residents, Doctoral Scientists, Pathologists’ Assistants, Laboratory Managers, Bench Supervisors, Bench Technologists and Technicians, Cytotechnologists, Histotechnologists, Students

  • List Price: $45.00
  • Member Price: $35.00
 
Want to save more?
Log into see if you qualify for a lower rate.
Members save $10.00 or more Join
Item Details:
Next-Generation Sequencing for Pediatric Tumors
Back to Next-Generation Sequencing for Pediatric Tumors

Bought This Bought That ...